DOI:
10.1055/s-00000056
Physikalische Medizin, Rehabilitationsmedizin, Kurortmedizin
LinksClose Window
References
Berenbaum F, Blanco FJ, Guermazi A. et al.
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and
safety results from a 24-week randomised phase III study with a 24-week
follow-up period.
Annals of the rheumatic diseases 2020;
79: 800-810
DOI: 10.1136/annrheumdis-2019-216296.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.